![IJMS | Free Full-Text | Prediction of Tacrolimus Exposure by CYP3A5 Genotype and Exposure of Co-Administered Everolimus in Japanese Renal Transplant Recipients IJMS | Free Full-Text | Prediction of Tacrolimus Exposure by CYP3A5 Genotype and Exposure of Co-Administered Everolimus in Japanese Renal Transplant Recipients](https://pub.mdpi-res.com/ijms/ijms-19-00882/article_deploy/html/images/ijms-19-00882-ag.png?1569941125)
IJMS | Free Full-Text | Prediction of Tacrolimus Exposure by CYP3A5 Genotype and Exposure of Co-Administered Everolimus in Japanese Renal Transplant Recipients
![These highlights do not include all the information needed to use EVEROLIMUS TABLETS safely and effectively. See full prescribing information for EVEROLIMUS TABLETS. EVEROLIMUS tablets, for oral useInitial U.S. Approval: 2009 These highlights do not include all the information needed to use EVEROLIMUS TABLETS safely and effectively. See full prescribing information for EVEROLIMUS TABLETS. EVEROLIMUS tablets, for oral useInitial U.S. Approval: 2009](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=image-01.jpg&id=598237)
These highlights do not include all the information needed to use EVEROLIMUS TABLETS safely and effectively. See full prescribing information for EVEROLIMUS TABLETS. EVEROLIMUS tablets, for oral useInitial U.S. Approval: 2009
![Frontiers | Low-Dose Everolimus Maintenance Therapy for Renal Angiomyolipoma Associated With Tuberous Sclerosis Complex Frontiers | Low-Dose Everolimus Maintenance Therapy for Renal Angiomyolipoma Associated With Tuberous Sclerosis Complex](https://www.frontiersin.org/files/Articles/744050/fmed-08-744050-HTML/image_m/fmed-08-744050-g001.jpg)
Frontiers | Low-Dose Everolimus Maintenance Therapy for Renal Angiomyolipoma Associated With Tuberous Sclerosis Complex
![A phase 1 trial of everolimus and bevacizumab in children with recurrent solid tumors - Santana - 2020 - Cancer - Wiley Online Library A phase 1 trial of everolimus and bevacizumab in children with recurrent solid tumors - Santana - 2020 - Cancer - Wiley Online Library](https://acsjournals.onlinelibrary.wiley.com/cms/asset/61f9376a-ccb0-47d6-93ef-4f6d2bea93cf/cncr32722-fig-0004-m.jpg)
A phase 1 trial of everolimus and bevacizumab in children with recurrent solid tumors - Santana - 2020 - Cancer - Wiley Online Library
![Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy | Breast Cancer Research | Full Text Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy | Breast Cancer Research | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13058-021-01394-y/MediaObjects/13058_2021_1394_Fig2_HTML.png)
Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy | Breast Cancer Research | Full Text
![Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer](https://larvolclin.s3.us-west-2.amazonaws.com/16675465114542993196364bd8f878e2.jpeg)
Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer
![Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours | British Journal of Cancer Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fsj.bjc.6604851/MediaObjects/41416_2009_Article_BF6604851_Fig1_HTML.jpg)
Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours | British Journal of Cancer
![Recommendations for the use of everolimus in de novo kidney transplantation: False beliefs, myths and realities - ScienceDirect Recommendations for the use of everolimus in de novo kidney transplantation: False beliefs, myths and realities - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2013251417300883-gr1.jpg)
Recommendations for the use of everolimus in de novo kidney transplantation: False beliefs, myths and realities - ScienceDirect
![Recommendations for the use of everolimus in de novo kidney transplantation: False beliefs, myths and realities | Nefrología Recommendations for the use of everolimus in de novo kidney transplantation: False beliefs, myths and realities | Nefrología](https://multimedia.elsevier.es/PublicationsMultimediaV1/item/multimedia/S2013251417300883:gr1.jpeg?xkr=ue/ImdikoIMrsJoerZ+w92lL8PRnKGMnsiVXV6EVJ5QRkjJZIKj2umwUyY+cL6K8cyMCoG0zLrx/ORKa7YTjKUFV05yVJIH/ZJ7/flQB1eTMrqzaTDYNJI1H3lyttyunA+GbiPUmXx7sXPO9Mv7sH3iE4MKKWC/FO6IoDweG3lWqGYxIgshRz6RbAC1a56prqbHf6JBOLbpFZE9n2ff+TwrIH8+f1UYf4CrjGhERlSvIZAxl4YXAoF7UYBfuS01uCfYZkXPkCiPJLDSvXV2ik3MpVWpoSq+1uq7leDx2TQn9fKu3PLPgsQCcV8Iq0YxE)
Recommendations for the use of everolimus in de novo kidney transplantation: False beliefs, myths and realities | Nefrología
![Recommendations of everolimus use in liver transplant | Gastroenterología y Hepatología (English Edition) Recommendations of everolimus use in liver transplant | Gastroenterología y Hepatología (English Edition)](https://multimedia.elsevier.es/PublicationsMultimediaV1/item/multimedia/S244438241730158X:gr1.jpeg?xkr=ue/ImdikoIMrsJoerZ+w997EogCnBdOOD93cPFbanNcRcp7AE8pxI7/lU7i5mKGl6o67DY/uL2+/IxZemV5MIqAjD3SWPjrFs2sOZiACxejbMkZu4oEPV0J6NaokwpWiG1nFpaRDyRli2l1herxyVsGMCRD2jAEjD7WF63r5Bu8tVTWLElZku03XssFmwWRcagaTB+vwnOJCxlMbkAwWymUei3llIz6ql6R1j81pNiu4BVKyUdRvMTpJCvzbFqRXdbEa3obE3+rF6VO0Dx/vZ3HE3gjSciV3k4wxzv+1Wu0=)
Recommendations of everolimus use in liver transplant | Gastroenterología y Hepatología (English Edition)
![Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study - The Lancet Oncology Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study - The Lancet Oncology](https://www.thelancet.com/cms/attachment/c0a6c9ba-bffc-44f2-b625-22ed37e02f08/gr1.gif)